Impax Laboratories Inc (NASDAQ:IPXL)

39.92
Delayed Data
As of 3:58pm ET
 -0.53 / -1.31%
Today’s Change
22.12
Today|||52-Week Range
41.39
+26.01%
Year-to-Date
Actavis' Xydalba Granted Marketing Authorisation in Europe - Analyst Blog
3:17pm / Zacks.com
Will DexCom (DXCM) Loss Better Estimates this Earnings? - Analyst Blog
Feb 23 / Zacks.com
Pacira Misses Earnings Estimates in Q4, Revenues In Line - Analyst Blog
Feb 25 / Zacks.com
Will Wright Medical (WMGI) Disappoint Earnings Again in Q4? - Analyst Blog
Feb 23 / Zacks.com
Novartis' Farydak Approved for Multiple Myeloma with Warning - Analyst Blog
Feb 24 / Zacks.com
What's in Store for Endocyte (ECYT) this Earnings Season? - Analyst Blog
Feb 20 / Zacks.com
Will Allscripts (MDRX) Surprise Earnings Estimates in Q4? - Analyst Blog
Feb 24 / Zacks.com
Can Greatbatch (GB) Keep the Earnings Streak Alive in Q4? - Analyst Blog
Feb 20 / Zacks.com
Assembly Biosciences (ASMB) in Focus: Stock Falls 7.4% - Tale of the Tape
Feb 24 / Zacks.com
Will Gogo's (GOGO) Earnings Beat Estimates this Season? - Analyst Blog
Feb 19 / Zacks.com
Earnings Scheduled For February 24, 2015
Feb 24 / Benzinga
Actavis Barred from Selling Generic Pulmicort Respules - Analyst Blog
Feb 18 / Zacks.com
Will Celldex Therapeutics (CLDX) Disappoint This Earnings? - Analyst Blog
Feb 23 / Zacks.com
Oncolytics' Reolysin Gets Another Orphan Drug Status - Analyst Blog
Feb 18 / Zacks.com
Pfizer Rapamune Under FDA Priority Review for Lung Disease - Analyst Blog
Feb 23 / Zacks.com
Teva to Commercialize Eagle's Cancer Drug in the U.S. - Analyst Blog
Feb 18 / Zacks.com
Will BioMarin (BMRN) Beat Estimates this Earnings Season? - Analyst Blog
Feb 23 / Zacks.com
Agile Therapeutics (AGRX) in Focus: Stock up 9.9% - Tale of the Tape
Feb 18 / Zacks.com
Will Exelixis (EXEL) Miss Estimates this Earnings Season? - Analyst Blog
Feb 23 / Zacks.com
Will Priceline (PCLN) Beat Earnings Estimates this Season? - Analyst Blog
Feb 17 / Zacks.com

To view my watchlist

Not a member yet?

Sign up now for a free account